Overview

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.

Phase:

Phase 3

Details

Lead Sponsor:

MacroGenics

Collaborator:

Eli Lilly and Company

Treatments:

Antibodies, Monoclonal